/PRNewswire/ Leading GMP cell CDMO I Peace, Inc. (https://www.ipeace.com), specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell.
Investegate announcements from Novo Nordisk A/S, Heartseed and Novo Nordisk announce first patient dosed in clinical study with HS-001 – a cell therapy designed to restore heart function in people with advanced heart failure
Heartseed Inc. (Heartseed) and Novo Nordisk A/S today announced that Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee has evaluated 4-week data on the patient .